Jefferies analyst Sean Dodge says his firm's updated market share analysis continues to show Teladoc as the dominant vendor. SimilarWeb data points to BetterHelp usage down quarter-over-quarter in November but stabilizing in December and up in January, Dodge tells investors in a research note. There are "multiple upcoming catalysts, giving investors a reason to own the stock now," says the analyst. He points out Teladoc shares are still down over 30% from their late-September highs. Dodge keeps a Buy rating on the stock with a $95 price target, which represents 57% upside potential.